Cellular immunogenicity and immunotoxicity assays help scientists design, validate, and translate therapeutic research into treatments that weaponize the immune response against cancer.

Biologic-based therapeutics are known to generate anti-drug immune responses or immunogenicity in clinical patients which can lead to altered pharmacokinetics, decreased drug efficacy, and unwanted ...

At PEPperPRINT, we developed a novel pipeline to enable: Profiling potential T-cell immunogenicity through chip-based MHC-associated peptide proteomics (MAPPs) assay Discrimination of regulatory T ...

Serum samples for anti-panitumumab antibody testing were collected from mCRC patients enrolled in 4 panitumumab clinical trials (20050184, 20060277, 20050181, and 20050203). Patients in these ...

The industry uses singleplex assays to detect and characterize ADA responses in a tiered sequential manner. This presentation will introduce the concepts of Immunogenicity and share a novel ...

Comparing the immunogenicity of currently used TNF-α ... making it difficult or impossible for a drug-sensitive assay to detect anti-etanercept antibodies. One approach to overcome this problem ...

In the vaccine efficacy and preclinical safety space, this includes immunogenicity assays, neurovirulence testing, antibody-dependent enhancement and vaccine-associated enhanced disease models and ...

PROVIDENCE, R.I., Dec. 6, 2024 /PRNewswire/ -- EpiVax, Inc., a leader in preclinical immunogenicity risk assessment for biologic and peptide therapeutics, celebrates a productive 2024 marked by ...

Robust and comparable immunogenicity was observed between adolescents and young adults who received 2- or 3-dose schedules of ...

Immunogenicity bioanalysis follows an industry-standard tiered-testing approach, including assay screening (all samples), ...